Literature DB >> 28529317

How much do clinical trials cost?

Linda Martin1, Melissa Hutchens1, Conrad Hawkins1, Alaina Radnov1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28529317     DOI： 10.1038/nrd.2017.70

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  29 in total

1.  Who cares about a label? The effect of pediatric labeling changes on prescription drug utilization.

Authors:  Christopher Ody; Matt Schmitt
Journal:  Int J Health Econ Manag       Date:  2019-03-18

Review 2.  Designing deep learning studies in cancer diagnostics.

Authors:  Andreas Kleppe; Ole-Johan Skrede; Sepp De Raedt; Knut Liestøl; David J Kerr; Håvard E Danielsen
Journal:  Nat Rev Cancer       Date:  2021-01-29       Impact factor: 60.716

Review 3.  Development and evaluation of addiction treatment programs in Latin America.

Authors:  Rodrigo Marín-Navarrete; María Elena Medina-Mora; Alejandro Pérez-López; Viviana E Horigian
Journal:  Curr Opin Psychiatry       Date:  2018-07       Impact factor: 4.741

Review 4.  Improving the Patient-Clinician Interface of Clinical Trials through Health Informatics Technologies.

Authors:  Jake Carrion
Journal:  J Med Syst       Date:  2018-05-29       Impact factor: 4.460

5.  Optimizing clinical trials recruitment via deep learning.

Authors:  Jelena Gligorijevic; Djordje Gligorijevic; Martin Pavlovski; Elizabeth Milkovits; Lucas Glass; Kevin Grier; Praveen Vankireddy; Zoran Obradovic
Journal:  J Am Med Inform Assoc       Date:  2019-11-01       Impact factor: 4.497

6.  Machine Learning Prediction of Clinical Trial Operational Efficiency.

Authors:  Kevin Wu; Eric Wu; Michael DAndrea; Nandini Chitale; Melody Lim; Marek Dabrowski; Klaudia Kantor; Hanoor Rangi; Ruishan Liu; Marius Garmhausen; Navdeep Pal; Chris Harbron; Shemra Rizzo; Ryan Copping; James Zou
Journal:  AAPS J       Date:  2022-04-21       Impact factor: 4.009

7.  Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.

Authors:  Chang-Keun Cho; Hye-Jung Park; Pureum Kang; Sungmin Moon; Yun Jeong Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2021-11-22       Impact factor: 4.946

8.  When Is an In Silico Representation a Digital Twin? A Biopharmaceutical Industry Approach to the Digital Twin Concept.

Authors:  Rui M C Portela; Christos Varsakelis; Anne Richelle; Nikolaos Giannelos; Julia Pence; Sandrine Dessoy; Moritz von Stosch
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 9.  Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial.

Authors:  Stephen J Greene; Eric J Velazquez; Kevin J Anstrom; Eric L Eisenstein; Shelly Sapp; Shelby Morgan; Tina Harding; Vandana Sachdev; Fassil Ketema; Dong-Yun Kim; Patrice Desvigne-Nickens; Bertram Pitt; Robert J Mentz
Journal:  JACC Heart Fail       Date:  2021-03-10       Impact factor: 12.035

Review 10.  Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials.

Authors:  Pishoy Gouda; Elie Ganni; Peter Chung; Varinder Kaur Randhawa; Guillaume Marquis-Gravel; Robert Avram; Justin A Ezekowitz; Abhinav Sharma
Journal:  Curr Cardiovasc Risk Rep       Date:  2021-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.